Efficacy Standards For 55 Diseases In 5 Years: FDA, Critical Path And CDISC’s Ambitious Plan

Building on the Alzheimer’s disease Therapeutic Area Standard, the groups hope to create measurement standards for clinical trials in a variety of therapeutic areas, but funding remains an acute challenge. In order to succeed, each project needs to be faster and cheaper than the Alzheimer’s effort.